Royalty Stream
Also known as: Music royalties, Pharma royalty, Mining royalty, Net smelter return
Buying a share of somebody else's revenue, forever or until a patent expires. Top-line exposure with no operating costs — and a valuation that lives or dies on the terminal assumption.
- Asset class
- Alternatives (real assets / IP)
- Instrument type
- Purchased revenue interest
- Traded
- Private transactions; some listed vehicles
- Typical users
- Specialist funds, pension funds, listed royalty companies
1 · SnapshotThe one idea to remember
2 · BeginnerWhat is it, really?
A royalty is a right to a percentage of revenue from something someone else operates. You buy the stream; they do the work.
The structural appeal is that a royalty sits at the top line, above every cost:
- Costs rise? The operator absorbs it; the royalty is unchanged.
- Capital expenditure needed? Not yours.
- Revenue rises? Your payment rises with it, automatically.
Three markets dominate, and they are more different than the shared label suggests:
- Music — a share of recording or publishing income. Long-lived, and transformed by streaming into a predictable annuity.
- Pharmaceutical — a share of a drug's sales, usually until patent expiry. Large, lumpy, and with a hard end date.
- Mining and energy — a share of production or net smelter return from a mine. Effectively perpetual commodity exposure with no operating risk.
3 · IntermediateHow it works in practice
The three markets compared
| Music | Pharma | Mining | |
|---|---|---|---|
| Duration | Decades; copyright terms are long | Ends at patent expiry | Mine life, often decades |
| Main risk | Taste and platform economics | Patent cliff, competition | Commodity price, mine viability |
| Cash-flow shape | Steady annuity | Ramp, plateau, cliff | Follows production and price |
| Predictability | High for catalogue works | High until the cliff | Price-dependent |
What drives the price
- The market quotes NPS multiples — price divided by annual net publisher share, or by annual royalty income. Catalogue deals have traded across a wide range, and the multiple is a compressed statement about duration and discount rate exactly as an equity multiple is.
- Rate sensitivity is severe. A long-duration cash-flow stream with no growth optionality is close to a very long bond. The 2022 rate rise repriced catalogue valuations sharply for exactly this reason, and nothing about the music changed.
4 · AdvancedPricing & valuation
Where the valuation actually breaks
- Decay is the central estimate in music. New releases earn heavily and decline; catalogue works older than roughly five years settle into a slow, predictable decay. Buying a recent hit means buying the decay curve at its steepest point, and the difference between assuming 3% and 8% annual decay swamps everything else in the model.
- The patent cliff is the central estimate in pharma. Revenue does not decline — it falls off a shelf when generics arrive, often losing most of its value within a year. The valuation is essentially a dated annuity, and the date is knowable.
- Mine life and grade are the central estimates in mining. A royalty on a mine that closes early is worth a fraction of the model; a royalty over a whole land package carries exploration upside the model usually excludes.
- In all three, most of the value sits in the terminal assumption — the same structural weakness the DCF calculator makes visible, with the added difficulty that the terminal period here is the least observable part of the asset.
The operational risks nobody models
- Collection and audit. Music royalties flow through collecting societies, distributors and publishers, and underpayment through misattribution is a documented and persistent problem. Serious buyers budget for audit as a line item.
- Contract reading. What exactly was sold — the recording, the composition, both, in which territories, for which uses? Rights are divisible in ways that create expensive surprises.
- Platform economics. Streaming payout formulas are set by private companies and have changed materially. A revenue share of a pool whose distribution rules can be rewritten is a weaker claim than it appears.
Why institutions bought in anyway
The case is genuine: long-duration, inflation-responsive cash flows with low correlation to equity markets are scarce, and pension funds need exactly that. The case's weakness is that it was made loudest when rates were near zero — when any long-duration cash flow looked attractive. Reassessed at higher discount rates, the asset class is smaller, cheaper and more honestly priced, which is a healthier place for it to be.
The formulas above are standard textbook formulations, simplified for teaching. They explain the mechanism — they are not a valuation tool, and they will not reproduce a dealer’s price.